Perrigo (PRGO) agrees to sell $380m infant formula business for $40m upfront as impairment looms

Perrigo Company plc (NYSE: PRGO) has agreed to sell its infant formula business to US contract manufacturer MeridianMade for up to $175 million, advancing a portfolio restructuring designed to concentrate capital on over-the-counter medicines and consumer self-care products. Announced on October 29, 2026, the transaction provides only $40 million in cash at closing, with another $135 million contingent on future performance milestones through 2030, despite the business generating $380 million in revenue over the preceding four quarters. Perrigo expects to recognise a non-cash impairment charge of $275 million to $375 million during the fourth quarter of 2026 and says the disposal should materially reduce future capital expenditure requirements. The agreement follows a strategic review initiated in November 2025, when management began reassessing the economics of maintaining a manufacturing-intensive nutrition business within its broader consumer healthcare portfolio. The central financial question is whether exiting a low-margin operation can improve Perrigo’s profitability and cash generation sufficiently to offset the loss of revenue and the limited guaranteed sale proceeds.

The proposed transaction would transfer a substantial US store-brand infant formula manufacturing operation to MeridianMade, a specialist platform focused on infant nutrition production and related services. Perrigo will continue owning and operating the business until completion, which is expected during the first half of 2027, subject to regulatory approvals and customary closing conditions. Both companies have emphasised continuity of production and customer supply during the transition, reflecting the importance of reliable manufacturing in a tightly regulated category.

For Perrigo, the disposal is part of a broader effort to simplify a business that has experienced declining sales, margin pressure and significant restructuring requirements. Management expects the remaining portfolio to offer a more attractive financial profile, but its latest quarterly results indicate that the underlying consumer self-care business still needs to demonstrate sustainable organic growth.

Why is Perrigo selling a $380 million infant formula business for only $40 million upfront?

The transaction’s financial structure creates a substantial difference between its announced maximum value and the amount Perrigo is contractually positioned to receive at completion. MeridianMade will pay $40 million in cash at closing, while additional consideration of up to $135 million depends on future performance milestones achieved through 2030. Consequently, approximately 77% of the maximum announced consideration is contingent rather than guaranteed.

The initial cash payment represents approximately 10.5% of the infant formula business’s $380 million trailing annual revenue. Even if all milestone conditions are satisfied, the full $175 million consideration would represent only about 0.46 times that historical sales figure. These comparisons illustrate the relationship between transaction consideration and revenue, but they should not be treated as an enterprise valuation multiple because the announcement does not disclose all assumptions concerning transferred assets, liabilities and working capital.

The low initial consideration becomes more understandable when the business’s earnings are examined. During the four quarters ended June 27, 2026, the infant formula operation generated only $8 million in segment adjusted operating income from $380 million in sales. That equates to an adjusted operating margin of approximately 2.1%, indicating that relatively little operating profit was generated from the reported revenue base.

This financial profile suggests that the business requires meaningful manufacturing scale and operational efficiency to deliver attractive returns. It also explains why an acquirer might structure much of the purchase consideration around future performance rather than paying the entire potential valuation immediately. The contingent arrangement allows Perrigo to participate in specified future improvements while transferring the ongoing operating responsibility to a buyer specialising in infant nutrition.

What does Perrigo’s expected $275 million to $375 million impairment reveal about the divestiture?

Perrigo expects to recognise a non-cash impairment charge ranging from $275 million to $375 million in the fourth quarter of 2026 in connection with the announced sale. The charge reflects an expected reduction in the accounting carrying value of the business or related disposal group under the applicable reporting requirements. It is not a cash payment to MeridianMade and should not be deducted directly from the $40 million closing consideration to calculate transaction cash proceeds.

The impairment nevertheless has implications for how investors assess the historical capital committed to the business. A sizeable write-down indicates that the financial value associated with the assets in Perrigo’s accounts exceeds the amount expected to be recovered through the transaction or related measurement assumptions. The precise accounting impact will depend on the final carrying values and the requirements applicable when the impairment is recognised.

The expected charge is substantially larger than the initial cash consideration, but the two figures measure different economic concepts. The closing payment describes money expected from the buyer, while the impairment concerns the seller’s accounting valuation of assets being disposed of. Combining them as though they represent separate cash losses would materially misstate the transaction.

Perrigo also expects to classify the infant formula business within discontinued operations beginning in the fourth quarter of 2026. This reporting change is planned before the anticipated transaction closing in 2027 and does not establish that ownership has already transferred. The company intends to include the business in its All In results for the third quarter, allowing investors to distinguish the reporting transition from the legal completion of the sale.

Why did Perrigo begin reconsidering its $240 million infant formula investment programme?

Perrigo initiated a strategic review of its infant formula business on November 5, 2025, as part of its Three-S plan to Stabilize, Streamline and Strengthen the group. The review included reassessing a previously announced $240 million investment programme intended to support the manufacturing network and improve operating capabilities. Management sought to evaluate whether continued investment in infant nutrition would generate returns consistent with the company’s broader capital allocation objectives.

The original investment programme addressed manufacturing capacity, packaging upgrades, quality processes and research and development capabilities. These are important requirements for an infant formula business, where production reliability and product specifications are central to commercial performance. However, the spending would also require Perrigo to commit substantial capital to a category generating relatively modest adjusted operating income.

During the second quarter of 2026, Perrigo implemented a partial shutdown at its Vermont facility as part of its Nutrition Network Optimization programme. Its regulatory filings described the action as a capacity rationalisation measure intended to improve the manufacturing footprint. The project also involved changes in selling expenses and other operating costs, contributing to improvements in quarterly segment profitability.

The proposed sale could eliminate the need for Perrigo to finance a significant portion of future infant formula manufacturing expenditure. However, the company has not published a fully reconciled figure identifying how much of the original $240 million programme remains unspent or will be avoided as a direct result of the transaction. The amount should therefore not be presented as a confirmed additional cash saving.

A more complete financial assessment would compare the capital expenditure avoided with the operating income and cash flow surrendered through the sale. Exiting the business could improve returns on capital if the released resources are deployed into higher-margin activities, but that outcome will depend on how Perrigo uses its remaining investment capacity.

Why was Perrigo’s infant formula business recovering operationally before the sale?

The proposed disposal follows a period of improvement in selected operating measures, making the decision more complex than the sale of a business experiencing uniformly deteriorating performance. During the second quarter of 2026, infant formula revenue increased 23.1% year on year to approximately $101 million from $82 million. The business also generated $4 million in segment operating income, compared with a $12 million loss in the corresponding quarter of 2025.

Perrigo attributed the revenue increase principally to the timing of contract manufacturing shipments and stronger store-brand formula sales. The operating improvement reflected higher sales, better manufacturing productivity and reduced selling expenses associated with the optimisation programme. Some of the year-on-year comparison also benefited from the absence of production variability that had adversely affected the prior-year quarter.

However, the business remained loss-making over the first six months of 2026. It generated $190.6 million in first-half sales, an increase of 12.3%, but recorded a segment operating loss of approximately $3.5 million. This contrasted with the positive second-quarter performance and demonstrates the importance of evaluating a longer period rather than extrapolating one improved quarter.

The trailing four-quarter adjusted operating margin of approximately 2.1% provides a broader perspective on the business’s economics. While operational recovery had begun, the company still faced the challenge of supporting specialised manufacturing infrastructure and future investment requirements. MeridianMade may be positioned to pursue further improvements through a business model dedicated entirely to infant nutrition, but the proposed sale does not establish that those improvements have already occurred.

Can removing infant formula improve Perrigo’s margins if its core consumer health business is still shrinking?

Perrigo’s second-quarter results show why portfolio simplification alone may not resolve the group’s profitability challenges. Core Perrigo, which excludes infant formula and specified previously announced disposals and exited products, reported revenue of approximately $907 million, down 3.1% from $936 million a year earlier. Core organic revenue declined 3.5%, reflecting weaker consumption and lower retail inventory levels despite management’s reported market-share improvements in selected categories.

Core adjusted operating margin declined to 13% from 14.6% during the comparable period, a contraction of 160 basis points. The decline reflected lower sales volumes, unfavourable product mix and reduced absorption of manufacturing costs, partly offset by savings from the Operational Enhancement Program. Core adjusted diluted earnings per share fell 20.7% to $0.46 from $0.58.

The contrast between Core Perrigo’s 13% quarterly adjusted operating margin and infant formula’s approximately 2.1% trailing adjusted operating margin helps explain the proposed disposal. Removing a low-margin operation can improve the margin percentage reported for the remaining portfolio, even if total group revenue declines. However, the ultimate effect also depends on shared costs, stranded expenses, accounting reclassifications and the amount of savings achieved after separation.

Perrigo’s August guidance anticipated a full-year Core adjusted operating margin of 15% to 16%, compared with 12.5% to 13.5% on the All In presentation used at that time. These ranges reflected management’s expectations before the latest transaction announcement and should not be interpreted as revised forecasts following the sale. The company has not yet provided a new financial outlook incorporating the completed separation of infant formula.

The next test for the remaining business will be whether organic sales stabilise while cost savings improve profitability. A higher reported margin resulting from a smaller portfolio would strengthen financial presentation, but sustainable earnings growth will still require healthier demand, effective pricing and continued operating improvements.

How could the infant formula divestiture affect Perrigo’s debt reduction and capital allocation strategy?

Perrigo’s balance sheet provides an important explanation for its emphasis on simplifying operations and reducing future capital expenditure. At June 27, 2026, the group held approximately $400 million in cash and cash equivalents against total debt of about $3.3 billion. The company has been using portfolio disposals and operating cash generation to strengthen financial flexibility, although the exact post-divestiture debt position has not yet been disclosed.

Earlier in 2026, Perrigo completed the sale of its dermacosmetics business, generating approximately $359 million in cash proceeds. Management reported applying the substantial majority of those proceeds towards reducing borrowings under its revolving credit facility. The transaction provides an established example of how Perrigo has used asset sales to support its financial restructuring.

The infant formula transaction is different because the guaranteed cash payment is comparatively small. At $40 million, the upfront proceeds would represent only about 1.2% of the debt outstanding at June 27, before transaction expenses or other adjustments. Even the maximum $175 million consideration would be modest relative to the reported borrowing balance, and most of that potential amount depends on future milestones.

The sale’s more meaningful financial benefit may therefore come from reduced future manufacturing investment and the removal of operating requirements associated with a low-margin business. If Perrigo can redirect capital towards products with stronger returns, the disposal could support improved cash generation over time. However, the company has not disclosed a precise forecast for future capital expenditure savings or incremental free cash flow attributable to the transaction.

Perrigo also continues to distribute cash to shareholders. On October 29, its board approved a quarterly dividend of $0.29 per share, payable on December 15 to shareholders of record on November 27. Maintaining dividends alongside debt reduction and portfolio investment creates an additional requirement for disciplined capital allocation.

What does MeridianMade gain from acquiring Perrigo’s US infant formula manufacturing business?

MeridianMade is a US infant nutrition manufacturing platform led by chief executive officer Ron Belldegrun and president Mia Funt. Its activities include contract manufacturing services covering spray drying, dry blending, packaging, research and development, regulatory support and commercialisation. The proposed acquisition would expand its position within the domestic infant formula manufacturing industry by adding Perrigo’s established operations and customer relationships.

Store-brand infant formula is an important component of the US consumer market because it provides alternatives to products marketed under major national brands. Retailers depend on manufacturers capable of meeting strict nutritional specifications and maintaining reliable production volumes. A specialised contract manufacturer may seek commercial advantages through dedicated infrastructure, technical expertise and relationships with multiple retail customers.

For MeridianMade, the acquired business offers an immediate revenue base, but its reported earnings indicate that improving manufacturing efficiency will be important. The buyer must manage the capital and operational requirements associated with production facilities, quality systems and customer contracts. The contingent purchase price also means that successful future performance could increase the amount ultimately paid to Perrigo.

The transaction does not disclose a complete integration plan, manufacturing capacity forecast or detailed investment programme under MeridianMade’s proposed ownership. Nor does it establish that the buyer will automatically improve operating margins simply because infant nutrition is its principal business. The commercial outcome will depend on production reliability, customer retention and the ability to generate returns after necessary manufacturing expenditure.

Perrigo and MeridianMade have stated that the infant formula operation will continue independently under Perrigo until completion. Maintaining supply continuity through the transition will be an important operating requirement for the buyer and seller, particularly where retailers and families rely on regular availability of infant nutrition products.

How could changing FDA requirements affect the transition of Perrigo’s infant formula operations?

The proposed ownership change takes place in a highly regulated manufacturing category. In the United States, infant formula is subject to specific Food and Drug Administration requirements covering nutrient composition, manufacturing controls, recordkeeping, labelling and product testing. These obligations apply independently of the financial arrangements between the buyer and seller, making quality assurance and regulatory compliance central to the transition.

The regulatory environment is also evolving. On October 29, the same date as Perrigo’s sale announcement, the FDA published a proposed rule that would update or reaffirm nutrient specifications for eight of the 30 nutrients required in infant formula. The agency is also seeking input on nutrients commonly added to products but not currently required under federal regulations.

The proposal forms part of a broader review of infant formula nutrient requirements and has not become a final regulatory standard. The FDA has indicated that manufacturers would receive appropriate implementation periods if future requirements change. Any resulting reformulation or manufacturing adjustments could create additional technical and operational work for participants across the industry.

The timing does not establish any causal relationship between the proposed FDA rule and Perrigo’s decision to sell. Perrigo’s strategic review began in November 2025, well before the latest regulatory proposal. Nevertheless, the evolving standards illustrate why operating an infant formula business requires sustained investment in scientific, manufacturing and quality capabilities.

MeridianMade will need to maintain compliance with the applicable requirements while managing any operational changes following closing. For Perrigo, successful separation will also depend on preserving supply commitments and completing the transaction without disrupting its remaining consumer health operations.

Why has PRGO stock shown limited reaction despite the scale of the proposed disposal?

Perrigo shares closed at $15.78 on October 30, 2026, down $0.12 or 0.75% from the previous session’s close of $15.90. The stock also declined modestly on October 29, the day the company announced the proposed sale. This trading pattern suggests that the immediate market response was relatively subdued compared with the scale of the announced impairment, although daily price movements cannot be attributed conclusively to any single development.

The shares were approximately 1.1% lower than their October 23 closing price of $15.96 but had gained about 6.9% during October. The October 30 price stood approximately 26% below the reported 52-week high of $21.33 and roughly 71% above the 52-week low of $9.23. The company’s equity market capitalisation was approximately $2.19 billion.

The pricing reflects a business undergoing restructuring rather than one whose turnaround has already been demonstrated through sustained earnings growth. Selling infant formula may remove a capital-intensive operation, but the limited upfront consideration means the transaction will not independently transform Perrigo’s borrowing position. Investors must also weigh the expected impairment against the potential improvement in future margins and capital expenditure.

Perrigo’s shares also continue to offer a substantial dividend yield based on the declared $1.16 annualised dividend and the October 30 market price. That calculation produces an indicative yield of approximately 7.4%, but it does not guarantee that future dividends will remain unchanged. The sustainability of shareholder distributions will depend on earnings, cash generation, debt obligations and future board decisions.

The company’s broader stock performance will be influenced by whether management delivers the cost savings and organic sales recovery outlined in its Three-S plan. The infant formula agreement contributes to portfolio simplification, but it provides no direct evidence that the remaining business has already overcome its demand and margin challenges.

What will Perrigo’s November 4 earnings reveal about the next stage of its turnaround?

Perrigo is scheduled to release its third-quarter 2026 financial results on November 4, providing the next opportunity to assess the underlying performance of the business before infant formula moves into discontinued operations. The results should offer updated figures for Core Perrigo revenue, profitability, cash generation and debt. They may also clarify management’s expectations following the announced divestiture.

The company will continue including infant formula in its All In results for the third quarter, while the fourth-quarter reporting presentation is expected to reflect the discontinued operations classification. Investors will need to compare these presentations carefully because changes in reported revenue and margins may reflect portfolio changes rather than equivalent improvements in the remaining operations. Updated reconciliations will be particularly important for evaluating year-on-year performance.

The transaction itself is expected to close during the first half of 2027, subject to the necessary approvals and other closing conditions. Completion would establish the timing of the initial $40 million payment and the transfer of the infant formula operations to MeridianMade. Subsequent milestone disclosures through 2030 will determine how much of the additional $135 million Perrigo ultimately receives.

The divestiture advances Perrigo’s effort to reduce portfolio complexity and concentrate on consumer self-care products, but it also exposes the cost of separating a manufacturing business whose revenue scale has not translated into attractive operating returns. The more important economic benefit may arise from lower future investment requirements than from the relatively modest guaranteed sale proceeds. Evidence of reduced capital expenditure, stronger Core Perrigo margins and improved operating cash flow after the separation would provide a more convincing measure of whether the restructuring is creating shareholder value.

Key takeaways from Perrigo’s infant formula divestiture and PRGO stock outlook

• Perrigo announced an agreement on October 29, 2026, to sell its infant formula business to MeridianMade for total potential consideration of $175 million.
• The buyer will pay $40 million in cash at closing, while up to $135 million remains conditional on performance milestones through 2030.
• The infant formula operation generated $380 million in trailing annual revenue but only $8 million in segment adjusted operating income, representing a margin of approximately 2.1%.
• Perrigo expects a fourth-quarter non-cash impairment charge of $275 million to $375 million associated with the planned transaction.
• The disposal follows a strategic review launched in November 2025 that included reassessing a previously announced $240 million infant formula investment programme.
• Core Perrigo reported second-quarter revenue of $907 million, down 3.1%, while Core adjusted operating margin declined to 13%.
• The sale is expected to reduce future manufacturing capital expenditure, although the company has not disclosed a quantified forecast for the savings.
• Perrigo held approximately $400 million in cash and $3.3 billion in debt at June 27, highlighting the importance of future cash generation and capital allocation.
• PRGO shares closed at $15.78 on October 30, down 0.75% for the session and approximately 26% below their reported 52-week high.
• The November 4 earnings announcement, first-half 2027 transaction closing and subsequent milestone payments will provide evidence of the restructuring’s financial impact.